tislelizumab
beigene,novartis
$bgne beigene announces late-breaking data at esmo gi showing overall survival benefit for tislelizumab plus chemotherapy in first-line advanced or metastatic esophageal squamous cell carcinoma 
GetOnTrade is a news platform to help you stay up-to-date with the latest stock market news. We are not financial advisor(please do your own due diligence).